Lantern Pharma Secures Third LP-284 Orphan Drug Status and Opens AI Hub
On Jan. 20 the FDA granted an orphan drug designation for LP-284 in soft tissue sarcomas, marking its third designation and Lantern Pharma’s sixth overall. On Jan. 12 the company opened an AI Center of Excellence in Bengaluru to scale its RADR platform and boost computational capacity.
1. FDA Grants Orphan Drug Designation for LP-284
On January 20 the FDA awarded orphan drug designation to LP-284 for treating soft tissue sarcomas, representing the molecule’s third such approval after mantle cell lymphoma and high-grade B-cell lymphoma. This designation extends regulatory exclusivity and potentially expedited review, bringing Lantern Pharma’s clinical pipeline to six orphan designations overall.
2. Establishing AI Center of Excellence in Bengaluru
On January 12 Lantern Pharma launched an AI Center of Excellence and Advanced Agentic Labs in Bengaluru to industrialize its proprietary RADR platform. The facility will expand computational capacity, large-scale data engineering and machine learning–ready disease models, enabling deeper integration with global biopharma and academic partners.